Alamar Biosciences, Inc.
ALMR · NASDAQ
Market closed$25.95$1.00 (+4.01%)After hours $25.95 · 0.00%
Key statistics
Previous close$24.95
Open$24.46
Day high$26.34
Day low$24.15
52-week high$29.43
52-week low$18.85
Market cap243.28M
Volume245.63K
Average volume323.06K
P/E ratio-14.91
Forward P/E—
EPS-1.74
Dividend yield0.00%
Market context
Why it moved
Alamar Biosciences (ALMR) surged today likely driven by positive investor sentiment and anticipation ahead of the company's upcoming Second Quarter 2026 financial results announcement scheduled for August 10, 2026, boosting buying momentum across the session.
What is happening
Recent company-specific developments and publisher coverage.
Longevity.Technology · July 17, 2026Alamar’s blood test breakthrough targets key Alzheimer’s markerGlobeNewswire · July 14, 2026Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026Yahoo Finance Singapore · July 13, 2026Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative DiseasesMoomoo · July 13, 2026BofA Securities Adjusts Alamar Biosciences Price Target to $30 From $27Quiver Quantitative · July 10, 2026Alamar Biosciences to Present NULISA Alzheimer’s Data in More Than 140 AAIC Posters and SessionsStock Titan · July 10, 2026New blood tests for Alzheimer’s take center stage at AAIC 2026Simply Wall Street · May 10, 2026Alamar Biosciences Revenue Jump And IPO Spotlight Neuro Focus PotentialGlobeNewswire · May 8, 2026Alamar Biosciences Reports First Quarter 2026 Financial Results Mt Newswire · July 13, 2026BofA Securities Adjusts Alamar Biosciences Price Target to $30 From $27 Mt Newswire · July 13, 2026Alamar Biosciences Partners With Research Universities on Neurodegenerative Biomarker Project Benzinga · May 12, 2026TD Cowen Initiates Coverage On Alamar Biosciences with Buy Rating, Announces Price Target of $30 Mt Newswire · May 12, 2026BofA Initiates Alamar Biosciences at Neutral With $27 Price Target Benzinga · May 12, 2026JP Morgan Initiates Coverage On Alamar Biosciences with Overweight Rating, Announces Price Target of $30 Mt Newswire · May 12, 2026JPMorgan Initiates Alamar Biosciences at Overweight With $30 Price Target Mt Newswire · May 12, 2026TD Cowen Initiates Alamar Biosciences at Buy With $30 Price Target Mt Newswire · May 12, 2026Leerink Initiates Alamar Biosciences at Outperform With $35 Price Target